Unknown

Dataset Information

0

PU.1 supports TRAIL-induced cell death by inhibiting NF-?B-mediated cell survival and inducing DR5 expression.

ABSTRACT: The hematopoietic Ets-domain transcription factor PU.1/SPI1 orchestrates myeloid, B- and T-cell development, and also supports hematopoietic stem cell maintenance. Although PU.1 is a renowned tumor suppressor in acute myeloid leukemia (AML), a disease characterized by an accumulation of immature blast cells, comprehensive studies analyzing the role of PU.1 during cell death responses in AML treatment are missing. Modulating PU.1 expression in AML cells, we found that PU.1 supports tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis via two mechanisms: (a) by repressing NF-?B activity via a novel direct PU.1-RelA/p65 protein-protein interaction, and (b) by directly inducing TRAIL receptor DR5 expression. Thus, expression of NF-?B-regulated antiapoptotic genes was sustained in PU.1-depleted AML cells upon TRAIL treatment and DR5 levels were decreased. Last, PU.1 deficiency significantly increased AML cell resistance to anthracycline treatment. Altogether, these results reveal a new facet of PU.1's tumor suppressor function during antileukemic therapies.

SUBMITTER: Haimovici A 

PROVIDER: S-EPMC5423115 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

PU.1 supports TRAIL-induced cell death by inhibiting NF-κB-mediated cell survival and inducing DR5 expression.

Haimovici Aladin A   Humbert Magali M   Federzoni Elena A EA   Shan-Krauer Deborah D   Brunner Thomas T   Frese Steffen S   Kaufmann Thomas T   Torbett Bruce E BE   Tschan Mario P MP  

Cell death and differentiation 20170331 5

The hematopoietic Ets-domain transcription factor PU.1/SPI1 orchestrates myeloid, B- and T-cell development, and also supports hematopoietic stem cell maintenance. Although PU.1 is a renowned tumor suppressor in acute myeloid leukemia (AML), a disease characterized by an accumulation of immature blast cells, comprehensive studies analyzing the role of PU.1 during cell death responses in AML treatment are missing. Modulating PU.1 expression in AML cells, we found that PU.1 supports tumor necrosis  ...[more]

Similar Datasets

Unknown Halting multiple myeloma with MALT1 inhibition: suppressing BCMA-induced NF-κB and inducing immunogenic cell death.
| S-EPMC11339052 | biostudies-literature
Unknown Structure-based identification of a new IAP-targeting compound that induces cancer cell death inducing NF-κB pathway.
| S-EPMC8649670 | biostudies-literature
Unknown Agonists of the TRAIL Death Receptor DR5 Sensitize Intestinal Stem Cells to Chemotherapy-Induced Cell Death and Trigger Gastrointestinal Toxicity.
| S-EPMC5001853 | biostudies-literature
Unknown TRAIL/NF-κB/CX3CL1 Mediated Onco-Immuno Crosstalk Leading to TRAIL Resistance of Pancreatic Cancer Cell Lines.
| S-EPMC6032098 | biostudies-literature
Unknown TRAIL death receptors DR4 and DR5 mediate cerebral microvascular endothelial cell apoptosis induced by oligomeric Alzheimer's A?.
| S-EPMC3388229 | biostudies-literature
Transcriptomics Halting Multiple Myeloma with MALT1 Inhibition: Suppressing BCMA-Induced NF-κB and Inducing Immunogenic Cell Death
2024-08-28 | GSE266548 | GEO
Unknown miR-133a Promotes TRAIL Resistance in Glioblastoma via Suppressing Death Receptor 5 and Activating NF-κB Signaling.
| S-EPMC5560119 | biostudies-literature
Unknown Structural basis of LaDR5, a novel agonistic anti-death receptor 5 (DR5) monoclonal antibody, to inhibit DR5/TRAIL complex formation.
| S-EPMC3436762 | biostudies-literature
Unknown A cell-penetrating peptide suppresses inflammation by inhibiting NF-κB signaling.
| S-EPMC3188757 | biostudies-literature
Unknown NF-κB-inducing kinase maintains T cell metabolic fitness in antitumor immunity.
| S-EPMC7855506 | biostudies-literature